Literature DB >> 26639405

A Comprehensive Map of CNS Transduction by Eight Recombinant Adeno-associated Virus Serotypes Upon Cerebrospinal Fluid Administration in Pigs.

Nicolina Cristina Sorrentino1, Veronica Maffia1, Sandra Strollo1, Vincenzo Cacace1, Noemi Romagnoli2, Anna Manfredi1, Domenico Ventrella2, Francesco Dondi2, Francesca Barone2, Massimo Giunti2, Anne-Renee Graham3, Yan Huang3, Susan L Kalled3, Alberto Auricchio4, Maria Laura Bacci2, Enrico Maria Surace5, Alessandro Fraldi6.   

Abstract

Cerebrospinal fluid administration of recombinant adeno-associated viral (rAAV) vectors has been demonstrated to be effective in delivering therapeutic genes to the central nervous system (CNS) in different disease animal models. However, a quantitative and qualitative analysis of transduction patterns of the most promising rAAV serotypes for brain targeting in large animal models is missing. Here, we characterize distribution, transduction efficiency, and cellular targeting of rAAV serotypes 1, 2, 5, 7, 9, rh.10, rh.39, and rh.43 delivered into the cisterna magna of wild-type pigs. rAAV9 showed the highest transduction efficiency and the widest distribution capability among the vectors tested. Moreover, rAAV9 robustly transduced both glia and neurons, including the motor neurons of the spinal cord. Relevant cell transduction specificity of the glia was observed after rAAV1 and rAAV7 delivery. rAAV7 also displayed a specific tropism to Purkinje cells. Evaluation of biochemical and hematological markers suggested that all rAAV serotypes tested were well tolerated. This study provides a comprehensive CNS transduction map in a useful preclinical large animal model enabling the selection of potentially clinically transferable rAAV serotypes based on disease specificity. Therefore, our data are instrumental for the clinical evaluation of these rAAV vectors in human neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26639405      PMCID: PMC4817820          DOI: 10.1038/mt.2015.212

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  29 in total

Review 1.  The choroid plexus and cerebrospinal fluid: emerging roles in development, disease, and therapy.

Authors:  Maria K Lehtinen; Christopher S Bjornsson; Susan M Dymecki; Richard J Gilbertson; David M Holtzman; Edwin S Monuki
Journal:  J Neurosci       Date:  2013-11-06       Impact factor: 6.167

2.  Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis I.

Authors:  Christian Hinderer; Peter Bell; Brittney L Gurda; Qiang Wang; Jean-Pierre Louboutin; Yanqing Zhu; Jessica Bagel; Patricia O'Donnell; Tracey Sikora; Therese Ruane; Ping Wang; Mark E Haskins; James M Wilson
Journal:  Mol Ther       Date:  2014-07-16       Impact factor: 11.454

Review 3.  Progress in gene therapy for neurological disorders.

Authors:  Michele Simonato; Jean Bennett; Nicholas M Boulis; Maria G Castro; David J Fink; William F Goins; Steven J Gray; Pedro R Lowenstein; Luk H Vandenberghe; Thomas J Wilson; John H Wolfe; Joseph C Glorioso
Journal:  Nat Rev Neurol       Date:  2013-04-23       Impact factor: 42.937

4.  AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial.

Authors:  Peter A LeWitt; Ali R Rezai; Maureen A Leehey; Steven G Ojemann; Alice W Flaherty; Emad N Eskandar; Sandra K Kostyk; Karen Thomas; Atom Sarkar; Mustafa S Siddiqui; Stephen B Tatter; Jason M Schwalb; Kathleen L Poston; Jaimie M Henderson; Roger M Kurlan; Irene H Richard; Lori Van Meter; Christine V Sapan; Matthew J During; Michael G Kaplitt; Andrew Feigin
Journal:  Lancet Neurol       Date:  2011-04       Impact factor: 44.182

5.  AAV-mediated photoreceptor transduction of the pig cone-enriched retina.

Authors:  C Mussolino; M della Corte; S Rossi; F Viola; U Di Vicino; E Marrocco; S Neglia; M Doria; F Testa; R Giovannoni; M Crasta; M Giunti; E Villani; M Lavitrano; M L Bacci; R Ratiglia; F Simonelli; A Auricchio; E M Surace
Journal:  Gene Ther       Date:  2011-03-17       Impact factor: 5.250

6.  Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy.

Authors:  Virginia Haurigot; Sara Marcó; Albert Ribera; Miguel Garcia; Albert Ruzo; Pilar Villacampa; Eduard Ayuso; Sònia Añor; Anna Andaluz; Mercedes Pineda; Gemma García-Fructuoso; Maria Molas; Luca Maggioni; Sergio Muñoz; Sandra Motas; Jesús Ruberte; Federico Mingozzi; Martí Pumarola; Fatima Bosch
Journal:  J Clin Invest       Date:  2013-07-01       Impact factor: 14.808

7.  Clinical biochemistry, haematology and body weight in piglets.

Authors:  A K Egeli; T Framstad; H Morberg
Journal:  Acta Vet Scand       Date:  1998       Impact factor: 1.695

Review 8.  Adeno-associated virus (AAV) gene therapy for neurological disease.

Authors:  Marc S Weinberg; R Jude Samulski; Thomas J McCown
Journal:  Neuropharmacology       Date:  2012-03-17       Impact factor: 5.250

9.  Efficacy of a combined intracerebral and systemic gene delivery approach for the treatment of a severe lysosomal storage disorder.

Authors:  Carmine Spampanato; Elvira De Leonibus; Paola Dama; Annagiusi Gargiulo; Alessandro Fraldi; Nicolina Cristina Sorrentino; Fabio Russo; Edoardo Nusco; Alberto Auricchio; Enrico M Surace; Andrea Ballabio
Journal:  Mol Ther       Date:  2011-02-15       Impact factor: 11.454

10.  Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy.

Authors:  Yong Hong Chen; Michael Chang; Beverly L Davidson
Journal:  Nat Med       Date:  2009-09-13       Impact factor: 53.440

View more
  7 in total

Review 1.  Gene therapy for Mucopolysaccharidoses.

Authors:  Kazuki Sawamoto; Hui-Hsuan Chen; Carlos J Alméciga-Díaz; Robert W Mason; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2017-12-26       Impact factor: 4.797

2.  Behavioral Assessment of Vision in Pigs.

Authors:  Francesca Barone; Eleonora Nannoni; Alberto Elmi; Carlotta Lambertini; Diana Gerardi Scorpio; Domenico Ventrella; Marika Vitali; José F Maya-Vetencourt; Giovanna Martelli; Fabio Benfenati; Maria L Bacci
Journal:  J Am Assoc Lab Anim Sci       Date:  2018-07-02       Impact factor: 1.232

Review 3.  Therapeutic Options for Mucopolysaccharidoses: Current and Emerging Treatments.

Authors:  Kazuki Sawamoto; Molly Stapleton; Carlos J Alméciga-Díaz; Angela J Espejo-Mojica; Juan Camilo Losada; Diego A Suarez; Shunji Tomatsu
Journal:  Drugs       Date:  2019-07       Impact factor: 11.431

4.  Age-Related 1H NMR Characterization of Cerebrospinal Fluid in Newborn and Young Healthy Piglets.

Authors:  Domenico Ventrella; Luca Laghi; Francesca Barone; Alberto Elmi; Noemi Romagnoli; Maria Laura Bacci
Journal:  PLoS One       Date:  2016-07-08       Impact factor: 3.240

Review 5.  Gene therapy for mucopolysaccharidoses: in vivo and ex vivo approaches.

Authors:  Alessandro Fraldi; Marta Serafini; Nicolina Cristina Sorrentino; Bernhard Gentner; Alessandro Aiuti; Maria Ester Bernardo
Journal:  Ital J Pediatr       Date:  2018-11-16       Impact factor: 2.638

6.  Development of Intrathecal AAV9 Gene Therapy for Giant Axonal Neuropathy.

Authors:  Rachel M Bailey; Diane Armao; Sahana Nagabhushan Kalburgi; Steven J Gray
Journal:  Mol Ther Methods Clin Dev       Date:  2018-02-15       Impact factor: 6.698

7.  Enhancing the Therapeutic Potential of Sulfamidase for the Treatment of Mucopolysaccharidosis IIIA.

Authors:  Nicolina Cristina Sorrentino; Vincenzo Cacace; Maria De Risi; Veronica Maffia; Sandra Strollo; Novella Tedesco; Edoardo Nusco; Noemi Romagnoli; Domenico Ventrella; Yan Huang; Nan Liu; Susan L Kalled; Vivian W Choi; Elvira De Leonibus; Alessandro Fraldi
Journal:  Mol Ther Methods Clin Dev       Date:  2019-10-28       Impact factor: 6.698

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.